Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tafluprost - Santen Pharmaceutical

Next Previous
X
Search
Drug Profile

Tafluprost - Santen Pharmaceutical

Alternative Names: AFP 168; DE-085; DE-118; MK-2452; Saflutan; Taflotan; Tapros; Tapros mini ophthalmic solution 0.0015%; Tapros ophthalmic solution 0.0015%; Zioptan

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Santen Pharmaceutical
  • Developer Merck & Co; Santen Pharmaceutical
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension

Most Recent Events

  • 22 Jan 2019 Santen Pharmaceutical completes a trial in Glaucoma and ocular hypertension in Taiwan (NCT04737928)
  • 03 Jul 2017 Santen Oy completes a phase I trial in Glaucoma and Ocular hypertension (In children, In adolescent) in USA, Hungary, Slovakia, Poland and United Kingdom (NCT02102750)
  • 01 Apr 2016 Preservative-free formulation launched for Glaucoma and Ocular hypertension in Singapore (Santen pipeline, July 2016)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top